Yi Wen Huang

Prof. Dr. Yi Wen Huang

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2016 in Liver International
Verified
Journal Article
Closed access
PDF file
TSTung‐Hung Su
Tung‐Hung Su
THTsung‐Hui Hu
Tsung‐Hui Hu
CCChi‐Yi Chen
Chi‐Yi Chen
YHYi-Hsiang Huang
Yi-Hsiang Huang
WCWan‐Long Chuang
Wan‐Long Chuang
TCthe C‐TEAM study group and the Taiwan Liver Diseases Consortium
the C‐TEAM study group and the Taiwan Liver Diseases Consortium

6 November 2017 in Nutrients
Verified
Journal Article
Open access
PDF file
CCChien-Chao Chiu
Chien-Chao Chiu
YCYung-Hao Ching
Yung-Hao Ching
YLYen-Peng Lee
Yen-Peng Lee
JLJu-Yun Liu
Ju-Yun Liu
YHYen-Te Huang
Yen-Te Huang
HCHsiao-Li Chuang
Hsiao-Li Chuang
Nonalcoholic fatty liver disease (NAFLD) is a serious liver disorder associated with the accumulation of fat and inflammation. The objective of this study was to determine the gut microbiota composition that might influence the progression of NAFLD. Germ-free mice were inoculated with feces from patients with nonalcoholic steatohepatitis (NASH) or from healthy persons (HL) and then fed a standard diet (STD) or high-fat diet (HFD). We found that the epididymal fat weight, hepatic steatosis, multifocal necrosis, and inflammatory cell infiltration significantly increased in the NASH-HFD group. These findings were consistent with markedly elevated serum levels of alanine transaminase, aspartate transaminase, endotoxin, interleukin 6 (IL-6), monocyte chemotactic protein 1 (Mcp1), and hepatic triglycerides. In addition, the mRNA expression levels of Toll-like receptor 2 (Tlr2), Toll-like receptor 4 (Tlr4), tumor necrosis factor alpha (Tnf-α), Mcp1, and peroxisome proliferator-activated receptor gamma (Ppar-γ) significantly increased. Only abundant lipid accumulation and a few inflammatory reactions were observed in group HL-HFD. Relative abundance of Bacteroidetes and Firmicutes shifted in the HFD-fed mice. Furthermore, the relative abundance of Streptococcaceae was the highest in group NASH-HFD. Nevertheless, obesity-related Lactobacillaceae were significantly upregulated in HL-HFD mice. Our results revealed that the gut microbiota from NASH Patients aggravated hepatic steatosis and inflammation. These findings might partially explain the NAFLD progress distinctly was related to different compositions of gut microbiota.

1 July 2016 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
YHYi Wen Huang
Yi Wen Huang
CLChia-Long Lee
Chia-Long Lee
SYSien-Sing Yang
Sien-Sing Yang
SFSzu-Chieh Fu
Szu-Chieh Fu
YCYun-Yi Chen
Yun-Yi Chen
DCDing-Shinn Chen
Ding-Shinn Chen
The protective effect of statins in cirrhosis and its decompensation in chronic hepatitis B (CHB) patients remains unknown. We conducted a population-based cohort study using data from the Taiwanese National Health Insurance Research Database from 1997 to 2009. A total of 298,761 CHB patients were identified. CHB patients using statins (n=6,543; defined as ≥28 cumulative defined daily doses (cDDD)) and a 1:1 ratio propensity score and inception point (the date of first use of statins)-matched non-statins (<28 cDDD) were followed up from the inception point until the development of cirrhosis or its decompensation or until withdrawal from insurance or December 2009. After adjustment for competing mortality, CHB patients using statins had a significantly lower cumulative incidence of cirrhosis (relative risk)=0.433; 95% confidence interval (CI)=0.344-0.515; modified log-rank test, P<0.001) and decompensated cirrhosis (relative risk=0.468; 95% CI=0.344-0.637; P<0.001) compared with patients not using statins. After adjustment for age, gender, comorbidity index, hypertension, diabetes, hyperlipidemia, hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, aspirin use, diabetes medication, CHB treatment, non-statin lipid-lowering drugs, and triglyceride lipid-lowering drugs using the Cox proportional hazard model, statins were still an independent protector against cirrhosis (adjusted hazard ratio (AHR)=0.512; 95% CI=0.413-0.634; P<0.001) and its decompensation (AHR=0.534; 95% CI=0.433-0.659; P365 cDDD of statins, respectively. CHB patients who receive statin therapy have a dose-dependent reduction in the risk of cirrhosis and its decompensation.

11 June 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
YHYi Wen Huang
Yi Wen Huang
SYSien-Sing Yang
Sien-Sing Yang
SFSzu-Chieh Fu
Szu-Chieh Fu
TWTing-Chuan Wang
Ting-Chuan Wang
CHCheng-Kai Hsu
Cheng-Kai Hsu
JKJia-Horng Kao
Jia-Horng Kao
The effect of diabetes on cirrhosis, its decompensation, and their time relationship in chronic hepatitis C (CHC) patients remains unclear. We conducted a nation-wide cohort study by using the Taiwanese National Health Insurance Research Database, which is comprised of data from >99% of the entire population. Among having randomly sampled 1 million enrollees, 6,251 adult CHC patients were identified from 1997 to 2009. Diabetes was defined as new onset in CHC patients who were given the diagnosis in the years 1999-2003, but not in 1997-1998. The cohorts of CHC with new-onset diabetes (n = 424) and nondiabetes (n = 1,708) were followed up from inception point in diabetes and from year 1999 in the nondiabetes cohort until development of cirrhosis or its decompensation, withdrawal from insurance, or December 2009. Kaplan-Meier's survival analysis showed a significantly higher cumulative incidence of cirrhosis (relative risk [RR] = 1.53; 95% confidence interval [CI] = 1.11-2.11; log-rank test; P < 0.001) and decompensated cirrhosis (RR = 2.01; 95% CI = 1.07-3.79; log-rank test; P < 0.001) among patients with new-onset diabetes, as compared to those without. After adjustment for age, gender, CHC treatment, diabetes treatment, hepatocellular carcinoma, comorbidity index, hypertension, hyperlipidemia, and obesity by Cox's proportional hazard model, diabetes was still an independent predictor for cirrhosis (hazard ratio [HR] = 2.505; 95% CI = 1.609-3.897; P < 0.001) and its decompensation (HR = 3.560; 95% CI = 1.526-8.307; P = 0.003). Conclusion: CHC patients who develop diabetes are at an increased risk of liver cirrhosis and its decompensation over time. (Hepatology 2014;60:807–814)

18 September 2013 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
YHYi Wen Huang
Yi Wen Huang
TWTing-Chuan Wang
Ting-Chuan Wang
SLShih-Chang Lin
Shih-Chang Lin
HCHan-Yu Chang
Han-Yu Chang
DCDing-Shinn Chen
Ding-Shinn Chen
JKJia-Horng Kao
Jia-Horng Kao
Background. The impact of diabetes on cirrhosis, its decompensation, and their time relationship in patients with chronic hepatitis B (CHB) remain unclear. Methods. We conducted a nationwide cohort study by using the Taiwanese National Health Insurance Research Database, which was comprised of data from >99% of the entire population. Among 1 million randomly sampled enrollees, 14 523 adult CHB patients were identified from 1997 to 2009. Diabetes was defined as newly diagnosed in CHB patients who were given the diagnosis in the years 1998–2001 but not in 1996–1997 and with physician visits of at least twice per year. The cohorts of CHB with newly diagnosed diabetes (n = 351) and without diabetes (n = 7886) were followed up from the diagnosis of diabetes and from 2000 in the patients without diabetes until development of cirrhosis or its decompensation, withdrawal from insurance, or December 2009. Results. Kaplan-Meier survival analysis showed a significantly higher cumulative incidence of cirrhosis (relative risk [RR] = 3.43; 95% confidence interval [CI], 2.62–4.49; P < .001, log-rank test) and decompensated cirrhosis (RR = 4.11; 95% CI, 2.95–5.70; P < .001, log-rank test) among patients with newly developed diabetes compared with those without diabetes. After adjustment for age, sex, CHB treatment, hepatocellular carcinoma, and comorbidity index by Cox proportional hazards model, diabetes was still an independent predictor for cirrhosis (hazard ratio [HR] = 2.015; 95% CI, 1.393–2.915; P < .001) and its decompensation (HR = 1.792; 95% CI, 1.192–2.695; P = .005). Conclusions. Patients with CHB who develop diabetes are at an increased risk of liver cirrhosis and its decompensation over time.

1 November 2010 in Antiviral Therapy
Verified
Journal Article
Closed access
TSTung-Hung Su
Tung-Hung Su
CHChing-Sheng Hsu
Ching-Sheng Hsu
CCChi-Ling Chen
Chi-Ling Chen
Chen-Hua LiuChen-Hua Liu
Chen-Hua Liu
YHYi Wen Huang
Yi Wen Huang
JKJia-Horng Kao
Jia-Horng Kao
Background: Serum HBV DNA level is crucial in the management of chronic hepatitis B (CHB); however, the assay is expensive and cannot be used widely. Therefore, we explored the possibility of hepatitis B surface antigen (HBsAg) quantification as a surrogate marker for HBV DNA level in CHB patients. Methods: A total of 289 CHB patients were enrolled, 251 were evaluated at baseline and 75 of them were also evaluated during anti-HBV treatment. Another 38 on-treatment patients were used for validation. Serum HBsAg titre was quantified by an immunoassay and HBV DNA level by a PCR-based method. Baseline and on-treatment data were analysed. Results: In parallel to log 10 HBV DNA, the log 10 HBsAg was high in both immune tolerance and immune clearance phases, and significantly decreased in the inactive carrier state and was again increased in the reactivation phase of the CHB infection. There was a positive correlation between log 10 HBsAg and log 10 HBV DNA, which was greater in patients with chronic hepatitis, hepatitis B e antigen- positivity, greater alanine aminotransferase or HBsAg levels at baseline and during pegylated interferon treatment. Log 10 HBsAg could predict log 10 HBV DNA independently. An HBsAg titre of >900 IU/ml at baseline or >1,500 IU/ml within the first year of treatment could predict an HBV DNA level of >20,000 IU/ml, especially in subgroups of chronic hepatitis with alanine aminotransferase levels >40 IU/l. The dynamics of HBsAg might also predict serial HBV DNA changes. In the validation group, 64% of patients with on-treatment HBV DNA levels >20,000 IU/ml could be correctly predicted. Conclusions: Serum HBsAg concentration might serve as a surrogate marker of HBV DNA level in CHB patients.